+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032- Product Image
Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032- Product Image
Sale

Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533182
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thyroid Cancer Diagnostics Market is projected to reach USD 3.72 Billion in 2026. It is expected to continue growing at a CAGR of 7.35%, reaching USD 5.71 Billion by 2032.

Thyroid cancer diagnostics are moving from single-test detection toward integrated thyroid nodule evaluation that combines high-resolution ultrasound, fine-needle aspiration cytology, molecular diagnostics, serum biomarkers, and risk-adapted follow-up. This shift is clinically important because WHO/IARC GLOBOCAN 2022 estimated more than 820,000 new thyroid cancer cases worldwide, making thyroid cancer one of the most frequently diagnosed endocrine malignancies.

Demand is being shaped by rising detection of thyroid nodules, broader access to imaging, expanding use of Bethesda System cytopathology, and guideline-driven efforts to distinguish indolent papillary thyroid cancer from aggressive disease. For diagnostic companies, laboratories, hospitals, and imaging networks, the growth opportunity is strongest where tests improve clinical confidence, reduce unnecessary thyroidectomy, and support precision oncology decisions for BRAF, RAS, RET, NTRK, TERT, and other actionable alterations.

Transformative Shifts Reshaping Thyroid Cancer Diagnostics

The thyroid cancer diagnostics landscape is being transformed by three evidence-based shifts: more disciplined ultrasound risk stratification, wider use of molecular testing for indeterminate nodules, and tighter integration between pathology and oncology. Systems such as ACR TI-RADS and ATA ultrasound patterns have made imaging interpretation more standardized, while Bethesda cytology categories continue to guide fine-needle aspiration management.

Molecular diagnostics are changing the value proposition. Rule-out and rule-in assays help clinicians manage Bethesda III and IV nodules, and next-generation sequencing panels can identify mutations and fusions relevant to targeted therapy in advanced thyroid cancer. At the same time, laboratories are adapting to stricter quality, reimbursement, and regulatory expectations, including the EU In Vitro Diagnostic Regulation and heightened scrutiny of laboratory-developed tests in the United States.

Cumulative Impact of Artificial Intelligence on Diagnostic Accuracy

Artificial intelligence is having a cumulative impact across the thyroid cancer diagnostics workflow rather than replacing clinicians outright. In ultrasound imaging, AI models are being developed to classify suspicious thyroid nodules, estimate malignancy risk, support lesion segmentation, and reduce inter-reader variability. In cytopathology, machine learning can assist slide review, cell pattern recognition, and triage of cases that require expert assessment.

The commercial value of AI depends on external validation, explainability, workflow integration, and performance across diverse populations. Peer-reviewed literature shows promising accuracy for thyroid nodule classification, but real-world adoption requires prospective validation, bias monitoring, cybersecurity safeguards, and clear clinical responsibility. The strongest near-term use cases are decision support, quality control, and prioritization of high-risk cases in imaging centers and pathology laboratories.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific represents a high-volume growth arena for thyroid cancer diagnostics due to large patient populations, expanding ultrasound access, and strong diagnostic infrastructure in China, Japan, South Korea, Australia, and increasingly India. North America remains a premium adoption region, supported by advanced endocrine oncology networks, broad molecular testing use, and established clinical guidelines in the United States and Canada.

Europe is defined by guideline consistency, public health systems, and the transition to EU IVDR-compliant diagnostic evidence, creating demand for clinically validated assays and traceable laboratory workflows. Latin America, led by Brazil and Mexico, is expanding access to ultrasound-guided fine-needle aspiration and reference laboratory testing, although reimbursement variability affects molecular test uptake.

The Middle East is investing in tertiary cancer centers, genomic medicine, and private hospital capacity, especially across GCC countries. Africa remains underpenetrated but strategically important, with opportunities tied to ultrasound availability, pathology workforce development, referral networks, and affordable thyroid cancer diagnostic tests that can be deployed across public health systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are gaining relevance as urban hospitals expand endocrine imaging and cytology services, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different levels of readiness for molecular thyroid cancer diagnostics. The GCC is characterized by high healthcare investment, fast adoption of advanced imaging, and centralized cancer care models that can support genomic testing for thyroid cancer.

The European Union is a major regulatory and evidence-generation hub because EU IVDR is increasing requirements for clinical performance, post-market surveillance, and laboratory quality documentation. BRICS countries collectively represent scale, with China, India, Brazil, Russia, and South Africa offering large patient pools but uneven access to advanced diagnostics.

G7 countries lead in premium diagnostics adoption, clinical guideline development, reimbursement sophistication, and integration of molecular testing into oncology pathways. NATO markets overlap with many high-income healthcare systems and are relevant for supply-chain resilience, cybersecurity standards, laboratory interoperability, and cross-border diagnostic technology procurement.

Key Country Insights for Thyroid Cancer Diagnostics Adoption

The United States leads in molecular thyroid cancer diagnostics, AI-enabled imaging evaluation, and specialized endocrine oncology pathways, while Canada emphasizes evidence-based adoption through provincial health systems. Mexico and Brazil are expanding ultrasound and cytology access, with Brazil offering a major Latin American opportunity for reference laboratory growth and hospital-based molecular testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established pathology networks, national cancer strategies, and growing use of risk-stratified thyroid nodule management. Russia has strong tertiary care capacity in major cities but faces access variability across regions.

China is scaling thyroid ultrasound, hospital-based pathology, and domestic molecular testing at significant volume. India presents long-term growth driven by population scale, urban specialty care, and private diagnostics expansion, while Japan and South Korea are advanced markets with high imaging penetration and sophisticated cancer centers. Australia combines guideline-led practice with strong pathology standards and digital health adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated thyroid nodule diagnostics that reduce unnecessary surgery, improve indeterminate cytology management, and align with ATA, NCCN, ACR TI-RADS, and Bethesda-based workflows. Products should demonstrate utility through real-world evidence, health-economic outcomes, and clear reporting that clinicians can act on.

Organizations should invest in interoperable platforms connecting ultrasound, cytology, molecular results, and longitudinal surveillance data. AI developers must focus on diverse training datasets, transparent performance metrics, prospective validation, and integration into radiology and pathology workflows. Commercial teams should tailor strategies by region, pairing premium genomic testing in mature markets with affordable ultrasound-guided cytology and centralized reference testing in emerging markets.

Research Methodology for Evidence-Based Market Analysis

This executive summary is grounded in a structured research methodology combining secondary research, regulatory review, clinical guideline analysis, and market triangulation. Core evidence sources include WHO/IARC GLOBOCAN cancer statistics, ATA and NCCN thyroid cancer guidance, ACR TI-RADS recommendations, Bethesda System cytopathology standards, peer-reviewed AI and molecular diagnostics literature, and public regulatory information from agencies such as the FDA and European Commission.

Insights were evaluated across test modality, clinical utility, reimbursement environment, regional infrastructure, and adoption barriers. Country and group-level assessments considered healthcare capacity, diagnostic access, oncology referral systems, laboratory maturity, and policy trends. The approach emphasizes verified, data-backed interpretation and avoids unsupported sizing or forecasting claims.

Conclusion: Precision and Workflow Integration Define the Future

Thyroid cancer diagnostics are entering a more precise, connected, and evidence-driven phase. The market is no longer defined only by detecting malignancy; it is increasingly focused on identifying which nodules require intervention, which patients can be monitored safely, and which advanced cancers need targeted therapy selection.

Growth will favor organizations that combine clinical credibility, workflow efficiency, molecular depth, AI-enabled decision support, and regional adaptability. As incidence, imaging utilization, and precision oncology expand, thyroid cancer diagnostics will remain a high-value segment for laboratories, imaging providers, device manufacturers, software developers, and integrated cancer care networks.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Thyroid Cancer Diagnostics Market, by Technology
7.1. Immunoassay
7.1.1. Chemiluminescence Immunoassay
7.1.2. ELISA
7.2. Immunohistochemistry
7.3. Next Generation Sequencing
7.3.1. Targeted Sequencing
7.3.2. Whole Exome Sequencing
7.3.3. Whole Genome Sequencing
7.4. Real Time PCR
7.4.1. Digital PCR
7.4.2. qPCR
8. Thyroid Cancer Diagnostics Market, by Sample Type
8.1. Blood Sample
8.2. Fine Needle Aspiration
8.3. Tissue Biopsy
9. Thyroid Cancer Diagnostics Market, by Biomarker Type
9.1. Epigenetic Markers
9.1.1. DNA Methylation
9.1.2. miRNA
9.2. Genetic Markers
9.2.1. BRAF
9.2.2. RAS
9.2.3. TERT
9.3. Protein Markers
9.3.1. Calcitonin
9.3.2. Thyroglobulin
10. Thyroid Cancer Diagnostics Market, by Application
10.1. Diagnosis
10.2. Prognosis
10.3. Recurrence Monitoring
10.4. Therapy Monitoring
11. Thyroid Cancer Diagnostics Market, by End User
11.1. Academic Research Institutes
11.1.1. Cancer Research Centers
11.1.2. University Laboratories
11.2. Ambulatory Care Centers
11.2.1. Imaging Centers
11.2.2. Specialized Clinics
11.3. Laboratories
11.3.1. Chain Laboratories
11.3.2. Independent Laboratories
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Asia-Pacific Thyroid Cancer Diagnostics Market
13. Europe Thyroid Cancer Diagnostics Market
14. North America Thyroid Cancer Diagnostics Market
15. Latin America Thyroid Cancer Diagnostics Market
16. Africa Thyroid Cancer Diagnostics Market
17. Middle East Thyroid Cancer Diagnostics Market
18. NATO Thyroid Cancer Diagnostics Market
19. G7 Thyroid Cancer Diagnostics Market
20. BRICS Thyroid Cancer Diagnostics Market
21. European Union Thyroid Cancer Diagnostics Market
22. ASEAN Thyroid Cancer Diagnostics Market
23. GCC Thyroid Cancer Diagnostics Market
24. China Thyroid Cancer Diagnostics Market
25. United States Thyroid Cancer Diagnostics Market
26. Japan Thyroid Cancer Diagnostics Market
27. India Thyroid Cancer Diagnostics Market
28. Germany Thyroid Cancer Diagnostics Market
29. United Kingdom Thyroid Cancer Diagnostics Market
30. Australia Thyroid Cancer Diagnostics Market
31. France Thyroid Cancer Diagnostics Market
32. South Korea Thyroid Cancer Diagnostics Market
33. Italy Thyroid Cancer Diagnostics Market
34. Canada Thyroid Cancer Diagnostics Market
35. Russia Thyroid Cancer Diagnostics Market
36. Brazil Thyroid Cancer Diagnostics Market
37. Mexico Thyroid Cancer Diagnostics Market
38. Spain Thyroid Cancer Diagnostics Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. Becton, Dickinson and Company
40.3. bioMérieux S.A.
40.4. Bruker Corporation
40.5. Canon Medical Systems Corporation
40.6. Danaher Corporation
40.7. DiaSorin S.p.A.
40.8. Exact Sciences Corporation
40.9. F. Hoffmann-La Roche Ltd
40.10. Foundation Medicine, Inc.
40.11. Fujifilm Holdings Corporation
40.12. GE HealthCare Technologies Inc.
40.13. Guardant Health, Inc.
40.14. Hitachi High-Tech Corporation
40.15. Hologic, Inc.
40.16. Illumina, Inc.
40.17. Koninklijke Philips N.V.
40.18. Mindray Bio-Medical Electronics Co., Ltd.
40.19. Myriad Genetics, Inc.
40.20. QIAGEN N.V.
40.21. Seegene Inc.
40.22. Siemens Healthineers AG
40.23. Sysmex Corporation
40.24. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. JAPAN THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. INDIA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. FRANCE THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. BRAZIL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. MEXICO THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL QPCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL QPCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL QPCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BLOOD SAMPLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BLOOD SAMPLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BLOOD SAMPLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DNA METHYLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DNA METHYLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DNA METHYLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BRAF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BRAF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BRAF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TERT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TERT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TERT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PROTEIN MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PROTEIN MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PROTEIN MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CALCITONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CALCITONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CALCITONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL THYROGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL THYROGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL THYROGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL THERAPY MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL THERAPY MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL THERAPY MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 153. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 154. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 155. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 160. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 162. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 163. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 164. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 197. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 198. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 199. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 200. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 201. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 202. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 203. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 204. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 205. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 206. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 207. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 208. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 210. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 211. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 212. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 229. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 231. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 232. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 233. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 234. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 235. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 236. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 237. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 238. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 239. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 242. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 243. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 244. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 245. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 246. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 247. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 248. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 249. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 250. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 251. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 252. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 253. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 254. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 255. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 256. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 258. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 259. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 260. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 261. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 262. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 263. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 264. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 265. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 266. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 267. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 268. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 269. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 270. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 271. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 272. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 274. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 275. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 276. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 293. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 294. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 295. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 296. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 297. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 298. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 299. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 300. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 301. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 302. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 303. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 304. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 305. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 306. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 307. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 308. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 309. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 310. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 311. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 312. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 313. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 314. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 315. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 316. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 317. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 318. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 319. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 320. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 322. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 323. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 324. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 325. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 327. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 328. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 329. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
TABLE 330. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 331. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 332. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 333. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
TABLE 334. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 335. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 336. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 337. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 338. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
TABLE 339. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
TABLE 340. CHINA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 341. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 342. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 343. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 344. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 345. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET

Companies Mentioned

The companies featured in this Thyroid Cancer Diagnostics market report include:
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMérieux S.A.
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Guardant Health, Inc.
  • Hitachi High-Tech Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Mindray Bio-Medical Electronics Co., Ltd.
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.72 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.71 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Head & Neck Cancer Diagnostics Market by Product Type, Technology, Cancer Type, Application, End User - Global Forecast 2026-2032 - Product Image

Head & Neck Cancer Diagnostics Market by Product Type, Technology, Cancer Type, Application, End User - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report by Cancer Type (Papillary Carcinoma, Follicular Carcinoma), Technique (Imaging, Biopsy), End Use, and Region with Growth Forecasts, 2025-2033 - Product Image

Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report by Cancer Type (Papillary Carcinoma, Follicular Carcinoma), Technique (Imaging, Biopsy), End Use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 100 Pages
  • Global
From
Thyroid Cancer Diagnostics Market Report 2026 - Product Image

Thyroid Cancer Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Thyroid Cancer Diagnostics Market - Global Strategic Business Report - Product Image

Thyroid Cancer Diagnostics Market - Global Strategic Business Report

  • Report
  • 374 Pages
  • Global
From
Thyroid Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Thyroid Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.